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m7246 Signal Transduction via G Proteins is Enhanosd inFibroblasts From Patients With Eaasntial
Hypertension
M. Montemurro, F. Pietruck, D. Rosskopf, R. Erbel, W. Siffert.
Univerait~tsklinikum Essen, Essen, Germany
Aim of the study was to determine whether non-transformed fibroblaste from
essential hypertensive vs. normotensive subjects express phenotypic differ-
ences. EBV-immotlalizad Iymphoblasts from the same group of essential
hypertensive patients display enhanced signal transductionand increased
proliferation.
We investigated primav skin fibroblasts from five hypertensive (HT) and
normotensive (NT) subjects (passages 5-20).
Cytosolic free [Ca2+ [Ca2+]was measured with the fluorescent dye Fura-
2, DNA-syntheaia by [3H]-thymidine incorporation.
Baseline [Ca2+] was identical in HT and NT (112*36 vs. 114*46 nM).
Weobsemd a significantly higher increase in [Ca2+] in HTva. NT (p -=0.05)
upon stimulation with 1 UM /ys&phosphatidic-acid (LPA) (S30 * 75 vs. 218
k 45 nM), 1 KM sphingosine-1-phosphate (403 * 19 vs. 227 * 44 nM) and
1 U/ml thrombin (121 & 17 vs. 46 * 6 nM). Pretreatment with pertussis-toxin
(PTX) (50 rig/ml; 16 h) abolished these differences. Furthermore we found
the PTX-sensitive component of the Ca-signal to be distinctly increased in
HT vs. NT upon stimulation with endothelin-1 and angiotensin Il.
Agonist-induced DNA-synthesis was significantly enhanced in HT VS.NT
(LPA: 196 vs. 152%, FCS: 435 vs. 214% above non-stimulated control).
These findings confirm our earlier observations that differences between
HT and NT are due to enhanced Gi-protein activation and further extend
them to vaeoactive agents and non-transformed cells. Differences in signal
transduction persist in the absence of a neurohumoral hypertensive milieu,
i.e. in cell culture, providing evidence for a genetically fixad mechanism.
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~1 LDLchO,es~arO,and ~n,iO~~aPhi~p~O~ressi~nin
the QUIET Trial
L. Cashin-Hemphill, R.E. Dinsmore, R.C. Chan, S.N. Williams,
G. I-lolmvang, H.E. Haber, R.S. Lees for the QUIET Investigators. Boston
Heart Foundation, Cambridge, MA, USA
The QUinapril Ischemic Event Trial (QUIET) randomized 1750 low risk sub-
jects within 72 hre of successful PTCA to quinapril 20 mg (Q) or placebo
(P) for three yeara. The clinical endpoint was time to first cardiac iechemic
event in the full cohort. Follow-up angiograms were performed in 453 sub-
jects to assess atherosclerosis progression in non-intewened arteries. The
primary angiographic endpoint was categorical designation as progressor or
non-progressor baaed on a 0.40 mm diminution in minimum lumen diame-
ter (MLD) in at least one diseased, non-intervened artery. An additional 24
subjects who were randomly selscled for participation in the angiographic
substudy had cardiac ischemic events but did not have follow-up angiograms;
they were therefore included as categorical progressore. Progression in the
two groups was: Q, 110/234 (4’~o); P 119/243 (49’%.), p =- 0.05. Since
QUIET was designed to test whether Q therapy would decrease progression
of coronary atherosclerosis in normocholesterolemic subjects, we analyzed
the QCA data (n = 453 subjects) for change in MLD index (MLDI, mean
per patient), a prospective secondary endpoint of QUIET, stratified by LDL
cholesterol.
LDLat baseline Changein MLDI,mm (SE) p-value
Placsbo Quinapril
<130m@dL -0.11 (0.02) –0.13 (0.02) 0.40
?130 mg/dL –0.17 (0.02) –0.12 (0.02) 0.08
p-value 0.02 0.78
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R.E. Schmiader, S. John, M, Langenfeld, M. Schlaich, G. Weidinger,
H. Weihprecht. Depaflment of Medicine /w University of
Ertangen-Numberg, Germany
Totest whether endothelium-dependent vasodilation in the forearm improves
after reductionof LDL-cholesterol, reexamined inadouble-blind randomized
study 30 white patients (age: 50 ?C12 yre; 20 men, 10 women) with LDL-
cholesterol >16L)mg/dl before and after6 months of therapy with either HMG
COAreductase inhibitor fluvastatin 40 mg b.i.d. or placebo. LDL cholesterol
dropped by 77 * 34 m~dl (p c 0.001) in the fluvastatin group. Nitric oxide
system was testad by ifitraarterial infusion (brachial artery) of N-monomethyl
L-Arginin (L-NMMA 1, 2, 4 ~mol/min), acetylcholine (ACH 3, 12, 24, 48
@rein) alone and in combination with L-NMMA (4 #moVmin), and sodium
nitropruseide (NITRO 200, 800, 3200 ng/min).
:V
i.a.ACH24 i.a.ACH24
+ L44MMA4
Resu/fs: The increase in forearm bleed flow (by plethysmography) in
response to ACH was greater after than before therapy (p c 0.01) and thie
improvement could be blocked by simultaneous administration of L-NMMA
(eee graph). No significant difference to L-NMMA and NITRO was obeetiad
before andaftertherapy, intheplacebo and fluvastatin group. Thus, treatment
of hyparcholesterfnemia with the HMG COA reductase inhibitor fiuveetetin
improved bioactivity of nitric oxide synthesis in the endothelium.
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Patiants with Intermittent Claudication
M.B. Elam, J. Heckman, J.R. Crouse, D.B. Hunninghake, J.A. Herd,
M. Davidson, W. Forbes. University of Tennessee Center for the Health
Sciences, Memphis, TN, USA, Otauka America Pharmaceutical, Rockville,
MD, USA
Cilostazol (CL?) is a phoaphodiesterase inhibitor and vasodilator which ie
marketed in Japan for treatment of ischemic symptoms of peripheral vas-
cular disease (PVD), and is currently being.evaluated in the Unitad Statee
for treatment of symptomatic intermittent claudicstion (lC). C12 has been
shown to improve walking distance in patients with IC and also possesses
significant antiplatelet activity. In addition to its reported vascdilator and an-
tiplatelet effects,CLZh@sbaan proposed to have beneficial effecteon plasma
lipoproteins. Weexaminad theeffectof administration of CLZvereus Placeh
(P) on plasma lipoproteins in 169 patients with IC. Following 12 weeks of
therapy with 100 mg CLZ B.I.D. plasma triglyceride decreased 18% (p <
0.001). This was accompanied by small but significant (p <0.001 and p
< 0.01, respectively) increases in both plasma HDL-C (10%) and apoAl
(5.7%). Both HDL3and HDLz subfractions were increased by CCZ; however,
the greatest percentage increase was observed in HDL2. Individuals with
baseline elevatad baseline triglyceride (>160 mg/dl) or decreased HDL-C
(48 mg/dl) experienced the greateat changes in triglyceride and HDL-C
(-31% and +18%, respectively). There was a trend (3%) toward decreased
apeB on CLZ which when combined with increased apoAl resulted in a
significant (9.8%, p < 0.002) increase in the apoA1/apoB ratio. LDL-C and
Lp(a) concentrations were unaffected by CIZ These results indicate that in
addition to improving the symptoms of IC, CLZ may also favorably modify
plasma lipoproteins in patients with PAD. The mechanism of this effect of
CLZ on plasma lipoproteins is, at preeent, unknown.
In conclusion, although the primary angiographic endpoint of QUIET was
neutral, the more rapid progression of coronary atherosclerosis seen in
subjects with higher LDL cholesterol on placebo did not occur in subjects on
quinapril.
